Solarvest BioEnergy Inc.
SVS.V
Toronto Stock Exchange Ventures0.02
CAD
+0.00
- -
Solarvest BioEnergy Inc.
SVS.V
(Toronto Stock Exchange Ventures)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Solarvest BioEnergy Inc. (TSXV: SVS.H) is a Canada-based algae biologics company that develops and commercializes patented microalgae production platforms for high-value organic ingredients and sustainable bioproducts. The company specializes in algal-based systems producing organic Omega-3 docosahexaenoic acid (DHA), protein expression including bone morphogenetic protein (BMP) and human therapeutics, bio-hydrogen fuels via solar harvesting technology, and cannabinoid compounds such as cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC); its flexible platform enables diverse outputs like lipid compounds, algal biomass, and pharmaceutical-grade health supplements without chemicals, solvents, or heavy processing to preserve nutritional integrity. Founded in 2005 and headquartered in Vancouver, British Columbia, Solarvest targets nutraceutical, pharmaceutical, biofuel, and green commercial product markets primarily in Canada with global commercialization potential. In recent developments, the company announced the pending sale of its Summerville, Prince Edward Island manufacturing and R&D facility in September 2024, with proceeds earmarked for creditor obligations, asset maintenance, and operational priorities expected in November 2024; it elected a new board of directors in June 2024 to oversee restructuring following its transfer to the TSX Venture Exchange's NEX board in January 2024; and it received U.S. Patent Allowance for its algal juice media technology in July 2023, enhancing production methods for algal cell cultures and related products. These changes reflect a strategic focus on financial stabilization, intellectual property advancement, and divestment of non-core assets amid halted operations noted in 2023.